(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of -25.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Voyager Therapeutics's revenue in 2024 is $250,008,000.On average, 4 Wall Street analysts forecast VYGR's revenue for 2024 to be $2,520,092,099, with the lowest VYGR revenue forecast at $271,503,135, and the highest VYGR revenue forecast at $4,894,658,518. On average, 3 Wall Street analysts forecast VYGR's revenue for 2025 to be $4,659,319,600, with the lowest VYGR revenue forecast at $1,357,515,675, and the highest VYGR revenue forecast at $8,412,253,135.
In 2026, VYGR is forecast to generate $5,357,028,357 in revenue, with the lowest revenue forecast at $4,045,396,712 and the highest revenue forecast at $6,668,660,002.